GRAFALON

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, France, Ireland, Israel, Lithuania, Netherlands, Poland, Romania, Spain, Turkey.

Active ingredients

The drug GRAFALON contains one active pharmaceutical ingredient (API):

1	Antithymocyte immunoglobulin UNII D7RD81HE4W - LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN
	Antithymocyte immunoglobulin is a selective immunosuppressive agent mostly acting on T lymphocytes. Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs.
	Read more about Antithymocyte immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GRAFALON Concentrate for solution for infusion	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA04	Antithymocyte immunoglobulin (rabbit)	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1147777
ES	Centro de información online de medicamentos de la AEMPS	62759
FR	Base de données publique des médicaments	64898643
HR	Agencija za lijekove i medicinske proizvode	HR-H-421675779
IL	מִשְׂרַד הַבְּרִיאוּת	7997
LT	Valstybinė vaistų kontrolės tarnyba	1011088, 1011089
NL	Z-Index G-Standaard, PRK	62626
PL	Rejestru Produktów Leczniczych	100077235
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61725001, W61725002
TR	İlaç ve Tıbbi Cihaz Kurumu	8699684980023